R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Group of people in lab where Quillaja saponaria trees grow

Plants and vaccine adjuvants: BSI’s sustainable trees in a l...

This time last year, Croda Pharma and Botanical Solution Inc (BSI) announced that they’d entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutic

R&D

A greener catalysis: Talking sustainable, scalable chemistry...

As King’s College London (KCL) scientists are once more in the headlines – this time with new ‘plug and play’ drug delivery technology that could offer a

R&D

Overcoming challenges with maternal vaccine trials

Childhood vaccines have proven to be one of the most effective public health interventions to reduce infant and child mortality.

R&D

FT US Pharma and Biotech Summit: Live coverage

This week, pharmaphorum heads to the Big Apple for the FT US Pharma and Biotech Summit, a one-day event where executives from some of the world’s top pharma companies will come together to

R&D

Case Study: MHRA

Following MHRA approval of a clinical trial, a study on Nuwiq, a recombinant FVIII therapy for the treatment of haemophilia A, can proceed.

R&D

pharmaphorum podcast episode 132a - woman on her phone listening to headphones

In vitro gametogenesis: the science has to be right, and it ...

In vitro gametogenesis (IVG) holds much potential for same-sex couples and women of a more advanced age struggling with infertility, but the question is whether we’re quite there yet.